Tiziana Life Sciences PLC's (LON:TILS, NASDAQ:TLSA) Dr Kunwar Shailubhai tells Proactive London about its latest US patent for its TZLS-501 antibody. The treatment is being developed to help people with life-threatening effects of the coronavirus (COVID-19). This comes at a time when Tiziana has been awarded several patents for multiple projects with four key patents being issued in the last few weeks and three of these patents were issued on the same day.
Tiziana Life Sciences recieves US patent for Covid-19 treatment
Quick facts: Tiziana Life Sciences PLC
Price: 139 GBX
Market Cap: £265.71 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE